| abstract |
The present disclosure provides SARS-CoV-2 binding agents, including agents that bind to a SARS-CoV-2 spike glycoprotein. Such agents include antibodies that bind to SARS-CoV-2, including antibodies that bind to a SARS-CoV-2 spike glycoprotein. Such binding agents are useful, including in compositions and in methods of treating, preventing, or alleviating a SARS-CoV-2 related disease, disorder, or condition, including one or more symptoms of the disease, disorder, or condition. |